Yoon Hee Lee

Prof. Dr. Yoon Hee Lee


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JKJong Mi Kim
Jong Mi Kim
YLYoon Hee Lee
Yoon Hee Lee
GCGun Oh Chong
Gun Oh Chong
SLSae Rom Lee
Sae Rom Lee
DHDae Gy Hong
Dae Gy Hong
Objective: This study aimed to compare the surgical outcomes between robotic multi-site myomectomy (RMSM) and robotic single-site myomectomy (RSSM), using the da Vinci® SP surgical system and perform propensity score matching analysis to ensure inter-group comparability. Methods: This retrospective study included 105 patients who underwent either three-incision RMSM or RSSM using the da Vinci® SP surgical system. We retrospectively reviewed and compared surgical outcomes using 1:1 propensity score matching. Results: After 1:1 propensity score matching, there were no differences in the total operation time and estimated blood loss between the groups. The docking time (p < 0.0001) and duration of hospital stay (p = 0.0001) were significantly shorter in the RSSM group than in the RMSM group. Conclusions: The surgical outcomes of RSSM were comparable to those of RMSM. Moreover, compared to RMSM, RSSM using the da Vinci® SP surgical system has shorter docking and morcellation times, and duration of hospital stay.

Verified
Journal Article
Open access
PDF file
GCGun Oh Chong
Gun Oh Chong
SJShin Young Jeong
Shin Young Jeong
YLYoon Hee Lee
Yoon Hee Lee
SPShin-Hyung Park
Shin-Hyung Park
HLHyun Jung Lee
Hyun Jung Lee
YLYoon Soon Lee
Yoon Soon Lee
Objective: We sought to evaluate whether the 18F-fluorodeoxyglucose uptake normalization of the primary tumor to both the liver and blood pool and lymph nodes to both the liver and blood pool can enhance the discrimination for prognosis prediction in patients with cervical cancer. Methods: A total of 156 patients with cervical cancer (International Federation of Gynecology and Obstetrics stages IIB–IV) treated with concurrent chemoradiotherapy (CCRT) were enrolled. The maximum standardized uptake value (SUVmax) of tumor (tSUVmax) and the lymph node (nSUVmax) divided by the SUVmean of the liver (tumor-to-liver ratio (TLR) and node-to-liver (NLR)) and blood pool (tumor-to-blood ratio (TBR) and node-to-blood ratio (NBR)) were investigated. Univariate and multivariate analyses of disease-free survival (DFS) and overall survival (OS) were performed using clinical and metabolic parameters. A receiver operating characteristic curve analysis was performed to compare the accuracy of the metabolic parameters. Results: The multivariate analysis revealed that NLR (hazard ratio ((HR): 3.54; 95% confidence interval (CI): 1.53–8.19; p = 0.0032) and NBR (HR: 3.38; 95% CI: 1.02–11.19; p = 0.0457)) were independent prognostic factors for DFS, while TLR (HR: 4.16; 95% CI: 1.19–14.50; p = 0.0252), TBR (HR: 3.01; 95% CI: 1.04–8.70; p = 0.0415), NLR (HR: 4.84; 95% CI: 1.58–14.81; p = 0.0057), and NBR (HR: 6.87; 95% CI: 1.55–30.54; p = 0.0113) were significant prognostic factors for OS. The normalization of tSUVmax to the liver or blood pool enhanced the discrimination for prediction of recurrence (tSUVmax vs. TLR; p = 0.0056 and tSUVmax vs. TBR; p = 0.0099) and death (tSUVmax vs. TLR; p < 0.0001 and tSUVmax vs. TBR; p = 0.0001). Conclusions: The normalization of tSUVmax was an independent prognostic factor and improved the discrimination for the prediction of tumor recurrence and death in patients with locally advanced cervical cancer treated with CCRT.

30 November 2023 in Journal of Yeungnam Medical Science
Verified
Journal Article
Open access
JLJuhun Lee
Juhun Lee
JKJong Mi Kim
Jong Mi Kim
GCGun Oh Chong
Gun Oh Chong
DHDae Gy Hong
Dae Gy Hong
YLYoon Hee Lee
Yoon Hee Lee
Background: Over the last two decades, serum levels of anti-Müllerian hormone (AMH) have been shown to be reliable markers of ovarian reserve. This study aimed to compare baseline serum AMH levels and well-controlled clinical factors between patients with unilateral and bilateral ovarian endometriomas during the menstrual phase.Methods: We conducted a retrospective study. We enrolled 136 patients aged 18 to 36 years who were diagnosed with unilateral or bilateral ovarian endometriomas. Serum AMH levels of all patients and their latest two to three menstrual cycles were measured before surgery for ovarian endometriomas. The latest menstrual cycle length ranged from 26 to 30 days. Patients with irregular menstruation, a recent medication history of hormonal drugs other than oral contraceptive pills, a previous history of ovarian surgery, or any medical history influencing ovarian function were excluded. Results: Of the 136 patients, 76 (55.9%) had unilateral ovarian endometriomas and 60 (44.1%) had bilateral ovarian endometriomas. Serum AMH levels were not significantly different between the two groups in the follicular phase, luteal phase, or at any random time point. Conclusion: Serum AMH levels were not significantly different between unilateral and bilateral ovarian endometriomas in the follicular and luteal phases, or at any random time during the menstrual cycle when various confounding factors were excluded.

Verified
Journal Article
Open access
PDF file
JKJong Mi Kim
Jong Mi Kim
GCGun Oh Chong
Gun Oh Chong
NPNora Jee-Young Park
Nora Jee-Young Park
YCYeong Eun Choi
Yeong Eun Choi
JLJuhun Lee
Juhun Lee
JPJi Young Park
Ji Young Park
Objective: Residual cancer cells (RCCs) contribute to cancer recurrence either because of tumor spillage or undetectable pre-existing micrometastatic tumor clones. We hypothesized that the pathologic evaluation of intraoperative peritoneal washes may reveal RCCs. The aim of this study was to evaluate the survival impact of RCCs identified in intraoperative peritoneal washes and their correlation with clinicopathologic parameters following radical hysterectomy for cervical cancer. Methods: A total of 229 patients with cervical cancer who underwent radical hysterectomy with pelvic and/or paraaortic lymphadenectomy were included. The intraoperative peritoneal washes after surgery were filtered through a strainer and the presence of tumor cells in the residual aspirate was determined. Univariate and multivariate analyses of clinicopathological parameters were performed to identify predictors of recurrence. Results: RCCs in intraoperative peritoneal washes were identified in 19 patients (8.3%). Multivariate analysis revealed that deep stromal invasion (hazard ratio [HR], 13.32; 95% confidence interval [CI], 1.81–98.27; p = 0.0111), lymph node metastasis (HR, 2.00; 95% CI, 1.01–3.99; p = 0.0482), and neoadjuvant chemotherapy (HR, 2.34; 95% CI, 1.89–4.61; p = 0.0139) were associated with tumor recurrence. However, the presence of RCCs was not associated with tumor recurrence (HR, 2.60; 95% CI, 0.74–9.11; p = 0.1352). Multiple logistic regression analysis revealed that RCCs were associated with neoadjuvant chemotherapy (odds ratio [OR], 0.22; 95% CI, 0.05–0.99; p = 0.0488) and large tumor size (OR, 4.16; 95% CI, 0.77–22.48; p = 0.0981). Conclusions: Although the presence of RCCs in intraoperative peritoneal washes do not significantly impact survival outcomes, there was a tendency of inferior survival outcomes in patients with RCCs. RCCs were associated with neoadjuvant chemotherapy and large tumor size.

10 March 2026 in ESMO Open
Verified
Journal Article
Open access
SRS.Y. Ryu
S.Y. Ryu
BNB.H. Nam
B.H. Nam
MKM.H. Kim
M.H. Kim
WJW.I. Jang
W.I. Jang
CSC. Sitathanee
C. Sitathanee
SWS. Wilailak
S. Wilailak
The standard treatment for locally advanced cervical cancer is cisplatin-based chemoradiotherapy; however, the optimal dose and dosing schedule of cisplatin remain debated. The aim of this study was to compare the clinical outcomes of weekly cisplatin at 40 mg/m2 versus those of tri-weekly cisplatin at 75 mg/m2 during radiation in patients with locally advanced cervical cancer. In this prospective, randomized clinical trial, we enrolled 314 patients with stage IIB-IVA cervical cancer, randomly assigning them in a 1 : 1 ratio into two arms. The weekly arm received a weekly dose of 40 mg/m2 cisplatin for six cycles, whereas the tri-weekly arm received a tri-weekly dose of 75 mg/m2 cisplatin for three cycles, both concurrently with radiotherapy. The primary endpoints included 3-year recurrence-free survival according to a superiority design, with P < 0.05 indicative of statistical significance. Overall survival, toxicity profiles, and quality of life (QOL) were also analyzed. Chemotherapy delay was more frequent in the weekly arm than in the tri-weekly arm (P = 0.008). However, the 3-year recurrence-free survival rate between the two arms did not significantly differ (78.7% in the weekly arm, 84.1% in the tri-weekly arm; hazard ratio 0.71, 95% confidence interval 0.39-1.32, P = 0.28). The pattern of recurrence did not differ significantly between the two arms. Grade 3 and 4 hematological toxicities occurred less frequently in the tri-weekly arm (P < 0.001). Furthermore, the tri-weekly arm had better QOL scores across several domains compared with the weekly arm. In this study, tri-weekly cisplatin-based chemoradiotherapy was not statistically superior to a weekly schedule in terms of survival outcomes for patients with locally advanced cervical cancer. However, the tri-weekly regimen exhibited a more favorable toxicity profile and improved QOL compared with the weekly regimen. These results suggest tri-weekly cisplatin administration as a feasible alternative for chemoradiotherapy in cervical cancer.

7 August 2026 in Journal of Lower Genital Tract Disease
Verified
Journal Article
Open access
HYHee Yeun Yoon
Hee Yeun Yoon
HJHyo Sung Jeon
Hyo Sung Jeon
MKMin Ju Kim
Min Ju Kim
JKJong Mi Kim
Jong Mi Kim
YLYoon Hee Lee
Yoon Hee Lee
GCGun Oh Chong
Gun Oh Chong
Objective: Cervical cancer, primarily caused by human papillomavirus (HPV) infection, is commonly detected using polymerase chain reaction (PCR)-based assays. However, these methods are time-consuming and require specialized instrumentation. This study evaluated the diagnostic performance of the loop-mediated isothermal amplification (LAMP) assay as a rapid alternative for HPV detection compared with conventional PCR testing. Methods: This study included 933 nonpregnant women aged ≥19 years who underwent HPV testing for cervical cancer screening or follow-up. The HPV panel included 14 high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). Cervical swab samples underwent nucleic acid extraction followed by LAMP amplification using type-specific primers. Reactions were performed at 63 °C for 35 minutes, and results were interpreted colorimetrically (blue for positive, purple for negative). Results: Compared with PCR, the LAMP assay showed a sensitivity of 97.8% (95% CI: 94.4–100.0) for HPV types 16 and 18 and 100.0% (95% CI: 98.8–100.0) for the remaining high-risk types. Specificity across all types was 100.0% (95% CI: 98.8–100.0). The overall diagnostic accuracy was 99.5% (95% CI: 99.0–100.0). When all 14 HPV types were analyzed collectively, clinical sensitivity and specificity were 99.4% and 100.0%, respectively. Conclusions: The LAMP assay provides a rapid, simple, and accurate method for HPV detection and may serve as a useful point-of-care screening tool, particularly in resource-limited settings.